Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,131 public trials 2,034 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Active, not recruiting

Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

NCT04126200

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • GSK Investigational Site Atlanta, Georgia, United States
  • GSK Investigational Site Indianapolis, Indiana, United States
  • GSK Investigational Site Boston, Massachusetts, United States
  • GSK Investigational Site Grand Rapids, Michigan, United States
View all 38 locations
View Trial Details
Active, not recruiting

Obinutuzumab in Marginal Zone Lymphoma

NCT03322865

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Augusta-Kranken-Anstalt gGmbH Bochum, Germany
  • University Hospital Essen Essen, Germany
  • Universitätsklinikum Freiburg Freiburg im Breisgau, Germany
  • Universitätsmedizin Georg-August-University Göttingen, Germany
View Trial Details
Active, not recruiting

A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China

NCT07226752

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Affiliated Hospital of Hebei University Baoding, China
  • Beijing Cancer Hospital Beijing, China
  • Beijing Tongren Hospital, Capital Medical University Beijing, China
  • Peking University Third Hospital Beijing, China
View all 23 locations
View Trial Details
Active, not recruiting

A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)

NCT03821610

Conditions
Acute Lymphoblastic Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +9 more
Locations
  • Heart of England Nhs Foundation Trust Birmingham, United Kingdom
  • University Hospitals Birmingham Nhs Foundation Trust Birmingham, United Kingdom
  • University Hospitals Bristol Nhs Foundation Trust Bristol, United Kingdom
  • Cambridge University Hospitals Nhs Foundation Trust Cambridge, United Kingdom
View all 22 locations
View Trial Details
Active, not recruiting

Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas

NCT05400109

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
Locations
  • University of Iowa/Holden Comprehensive Cancer Center Iowa City, Iowa, United States
  • University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States
  • Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland, Ohio, United States
View Trial Details

Related conditions